Loading clinical trials...
Loading clinical trials...
The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of Wakefulness Test (MWT). ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Takeda
NCT06952699 · Narcolepsy Type 2
NCT06251063 · Narcolepsy Type 1, Narcolepsy Type 2, and more
NCT06555783 · Narcolepsy Type 2
NCT04096560 · Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
Sleep Disorders Center of Alabama
Birmingham, Alabama
Mayo Clinic Arizona-PPDS
Scottsdale, Arizona
Stanford Center for Sleep Sciences and Medicine
Redwood City, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions